Proven Sites.
Engaged Physicians.
Predictable Performance.
Tekton Research is the multi-specialty site network built to help Sponsors and CROs activate sites efficiently, reach the right patient populations, and consistently execute at a high level.
The Tekton Blueprint
Built to Streamline Your Study Team's Processes and Enhance Trial Performance
A physician-led research model
Tekton carefully vets and selects established practicing physicians who bring clinical credibility, therapeutic expertise, and trusted patient relationships to research.
Paired with dedicated, full-time site staff and a centralized operational infrastructure, this physician-led model improves access to specialized populations and drives stronger enrollment, retention, adherence, and data integrity.
Feasibility grounded in clinical and operational fit
Centralized feasibility brings site and investigator input into one coordinated process. When appropriate, clinical and therapeutic experts contribute protocol review to help identify the sites most likely to fit the study and the populations it needs to reach.
With Tekton, opportunities are vetted through the realities of physician access, participant populations, site infrastructure, staffing, competing studies, and local execution.
This is one reason Tekton is strategically aligned with or a preferred partner for nine leading CROs.
Coordinated startup, clear ownership
Tekton centralizes key activities across regulatory, regulatory submissions, budgets, and site preparation, giving your study team a more consistent path from selection through activation.
Days from activation to FPI
A single point of coordination surfaces risks earlier, aligns sites around study requirements, and keeps responsibilities visible as the study moves toward FPI.
Recruitment: Activate fast, enroll early
Tekton treats enrollment as a connected system, not a last-mile tactic. Feasibility, physician databases, centralized recruitment, and site-level follow-up work as one to support your trial.
Tekton's Austin-based recruitment center drives strategy and execution across every site, with accountability underwritten at the site and study level.
Behind these processes sits a database of 340,000+ profiled participants, supplemented by physician referrals, community relationships, and disease-specific group access.
Retention: A unique Tekton advantage
Retention is shaped by the daily experience of participating in a trial. Clear communication, reliable scheduling, trusted site teams, and thoughtful visit support all influence adherence and continuity.
Tekton's physician relationships and dedicated research teams create a consistent local presence for participants, while centralized oversight helps sites stay aligned with protocol requirements.
That's what has driven an average 95% participant retention rate across Tekton studies (includes general medicine and vaccine studies).
Quality treated as an essential component of delivery
Tekton brings quality assurance, regulatory, clinical data, and risk management into study preparation and ongoing site execution.
Central teams support protocol training, source and electronic data capture review, document management, compliance tracking, corrective action, and inspection readiness.
Tekton's structure helps identify risk earlier, reinforce consistent processes, and protect participant safety and data integrity throughout your trial. Because Tekton partners with engaged practicing physicians rather than revenue-first relationships, that alignment holds from the start.
Areas of Excellence
Tekton's veteran site staff and investigators bring depth and expertise to highly specialized, complex trials.
Cardiometabolic
Partner with sites that set the standard for type 1 and type 2 diabetes, obesity, MASH/MASLD, thyroid, endocrinology, and related multi-comorbidity research.
Vaccines & Infectious Disease
Accelerate vaccine trials across 20+ sites with high-volume experience in flu, RSV, COVID-19, hMPV, herpes, and combination vaccines, as well as diagnostic studies.
Neurology & Psychiatry
Tap investigators with decades of practice history and ready patient populations in depression, pain, Alzheimer's, migraine, addiction, and other neurologic and psychiatric conditions.
General Medicine
Reach sites with high-volume trial experience and large, well-profiled populations for obesity, allergy, COPD, asthma, atopic dermatitis, diagnostics, and more.
Therapeutic Expertise
Leading investigators and real community-driven patient access enable Tekton to recruit hard-to-reach populations without sacrificing speed or scale.
Experience
- Addiction (drug/substance use disorders, alcohol use disorder, smoking and nicotine cessation)
- Allergy and Immunology
- Cardiology/Cardiovascular (hypertension, lipid disorders/dyslipidemia)
- Cognitive and Memory Disorders
- Consumer Health and Over-the-Counter
- Dermatology
- Diagnostics
- Endocrinology and Metabolism (type 1 diabetes, type 2 diabetes, obesity and weight management, dyslipidemia, thyroid disorders)
- Family Medicine
- Gastroenterology
- Hematology
- Infectious Diseases
- Inflammation
- Internal Medicine
- MASH/MASLD
- Medical Devices
- Nephrology
- Neurology (neurodegenerative diseases, Alzheimer’s disease and other dementias, Parkinson’s disease, multiple sclerosis, epilepsy, migraine and headache disorders, cognitive impairment and memory loss)
- Oncology
- Pain (acute, chronic, neuropathic)
- Psychiatry and Behavioral Health (depression, anxiety disorders, bipolar disorder, schizophrenia, ADHD, sleep disorders)
- Pulmonology and Respiratory Disease (asthma, COPD, respiratory infections)
- Rheumatology
- Vaccines
Specialty Populations
- People with multiple chronic conditions or comorbidities
- Pediatrics
- Adolescents
- Geriatrics
- Pregnant and postpartum
- Immunocompromised
- Neurodegenerative
- Neurodivergent
- Racially and ethnically diverse populations
- Rare disease
- Healthy volunteers
- Caregivers and care partners
Case Studies
-
Case Study: GLP-1 Medication Research Study
Read Case Study »Tekton met enrollment goals for a GLP-1 study in Moore, OK three months early, with a one-day regulatory turnaround.
-
Case Study: Phase 2 Migraine Research Study
Read Case Study »Tekton delivered a Phase 2 migraine study in Yukon, OK with 100% patient retention and a 1.5-day regulatory turnaround.
-
Case Study: Achieving 120% of Enrollment Targets for a Teen Cytomegalovirus (CMV) Trial at 5 Sites
Read Case Study »Tekton achieved an average of 172% enrollment across three sites, enrolling more than 30 patients in a recent Type 1 Diabetes clinical trial.
-
Case Study: Advancing Glucose Monitoring for Pregnant Women with Diabetes
Read Case Study »Tekton reached 240% of enrollment goals, enrolling 12 patients in a CGM study for pregnant women with diabetes.
-
Study Performance: Achieving 170% of Enrollment Targets for a Type 1 Diabetes Trial at 3 Sites
Read Case Study »Tekton averaged 172% enrollment across three sites, enrolling 30+ patients in a Type 1 Diabetes clinical trial.
-
Study Performance: Accelerating Alzheimer’s Disease Research
Read Case Study »Tekton Research averaged a one-day turnaround from site activation to first patient visit across seven sites in a recent Phase 3 norovirus vaccine trial.
-
Case Study: Fast-Tracking Enrollment for a Global Phase 3 Norovirus Vaccine Trial
Read Case Study »Tekton Research achieved an average of one day from site activation to first patient visit across seven sites in a Phase 3 norovirus vaccine trial.
-
Case Study: Achieving 172% of Enrollment Targets for a Global Phase 3 Trial
Read Case Study »Tekton achieved an average of 172% enrollment across seven sites, enrolling more than 720 patients in a 2024 Global Phase 3 vaccine clinical trial.
Partners & Affiliates
